U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H26ClN3O3.C4H6O4
Molecular Weight 485.958
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRUCALOPRIDE SUCCINATE

SMILES

OC(=O)CCC(O)=O.COCCCN1CCC(CC1)NC(=O)C2=C3OCCC3=C(N)C(Cl)=C2

InChI

InChIKey=QZRSNVSQLGRAID-UHFFFAOYSA-N
InChI=1S/C18H26ClN3O3.C4H6O4/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;5-3(6)1-2-4(7)8/h11-12H,2-10,20H2,1H3,(H,21,23);1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI
Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin 5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RESOLOR

Approved Use

Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7 ng/mL
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PRUCALOPRIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
109 ng × h/mL
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PRUCALOPRIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 day
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PRUCALOPRIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PRUCALOPRIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Disc. AE: Nausea, Headache...
Other AEs: Headache, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Nausea (2%)
Headache (1%)
Diarrhea (1%)
Abdominal pain (1%)
Other AEs:
Headache (19%)
Abdominal pain (16%)
Upper abdominal pain (16%)
Lower abdominal pain (16%)
Abdominal tenderness (16%)
Abdominal discomfort (16%)
Epigastric discomfort (16%)
Nausea (14%)
Diarrhea (13%)
Abdominal distension (5%)
Dizziness (4%)
Vomiting (3%)
Flatulence (3%)
Fatigue (2%)
Nausea (2%)
Headache (1%)
Diarrhea (1%)
Abdominal pain (1%)
Headache (19%)
Abdominal pain (16%)
Upper abdominal pain (16%)
Lower abdominal pain (16%)
Abdominal tenderness (16%)
Abdominal discomfort (16%)
Epigastric discomfort (16%)
Nausea (14%)
Diarrhea (13%)
Abdominal distension (5%)
Dizziness (4%)
Vomiting (3%)
Flatulence (3%)
Fatigue (2%)
Sources:
10 mg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
healthy
n = 60
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 1%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Diarrhea 1%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Headache 1%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal pain 1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Diarrhea 1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Headache 1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Diarrhea 13%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Diarrhea 13%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Nausea 14%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Nausea 14%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal discomfort 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal discomfort 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal tenderness 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal tenderness 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Epigastric discomfort 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Epigastric discomfort 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Lower abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Lower abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Upper abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Upper abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Headache 19%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Headache 19%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Fatigue 2%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Fatigue 2%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Nausea 2%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Nausea 2%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Flatulence 3%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Flatulence 3%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Vomiting 3%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Vomiting 3%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Dizziness 4%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Dizziness 4%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal distension 5%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal distension 5%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >=300 uM]
no [IC50 >=300 uM]
no
no
no
no
no
no
no
no
weak
yes [IC50 38 uM]
weak (co-administration study)
Comment: administered with dextromethorphan; in vivo DDI potential via inhibition of CYP2D6 appears low at the proposed dose
Page: 188.0
yes [IC50 4 uM]
yes [IC50 69 uM]
yes [IC50 7.8 uM]
yes [IC50 9.4 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes [Km 116 uM]
yes [Km 15 uM]
yes
weak (co-administration study)
Comment: co-administration of ketoconazole increased the Cmax and AUCtau of prucalopride at steady state by 38% and 37%, respectively; Administration of erythromycin, probenecid, cimetidine, and paroxetine did not have a significant effect on the PK of prucalopride (<10% change in Cmax and AUC)
Page: 100;187
Tox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant.
2000 Feb
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
2001
Serotoninergic neuroenteric modulators.
2001 Dec 15
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
2001 Jun 29
Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle.
2001 Nov
The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein.
2001 Nov 30
Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs.
2001 Oct
Central serotonin4 receptors selectively regulate the impulse-dependent exocytosis of dopamine in the rat striatum: in vivo studies with morphine, amphetamine and cocaine.
2002 Dec
Emerging treatments for irritable bowel syndrome.
2002 Jan
Irritable bowel syndrome: update on pathogenesis and management.
2002 Jan-Mar
Prucalopride, a systemic enterokinetic, for the treatment of constipation.
2002 Jul
New and emerging treatments for irritable bowel syndrome and functional dyspepsia.
2002 May
Gateways to clinical trials.
2002 Oct
5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphé nucleus 5-HT neuronal activity.
2002 Sep
Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial.
2003
[Visceral hypersensitivity: a concept within our reach].
2003 Jan
The serotonin 5-HT4 receptor and the amyloid precursor protein processing.
2003 Jan-Feb
Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.
2003 Jun
Gateways to clinical trials.
2003 May
Gateways to clinical trials.
2003 Oct
Gastrointestinal motility disorders and gastrointestinal prokinetic therapy.
2003 Sep
Effect of enterokinetic prucalopride on intestinal motility in fast rats.
2003 Sep
Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease.
2004
New and emerging treatment options for chronic constipation.
2004
Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum.
2004 Jun
Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists.
2005 Apr 15
5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice.
2007 Apr
Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
2007 Aug
The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
2007 Jan
Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract.
2007 Jan
The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph.
2007 Jan 12
Gateways to clinical trials. July-August 2008.
2008 Jul-Aug
Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice.
2008 Mar 5
Gateways to clinical trials.
2008 Oct
Gateways to clinical trials.
2008 Sep
Prucalopride.
2009
Translating 5-HT receptor pharmacology.
2009 Dec
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
2009 Mar
Effect of ICU interventions on gastrointestinal motility.
2010 Apr
Prucalopride for constipation.
2010 Feb
Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation.
2010 Feb
[New drugs for the treatment of constipation].
2010 Jul
Patents

Patents

Sample Use Guides

Adults: 2 mg once daily with or without food, at any time of the day.
Route of Administration: Oral
Cell shortening and real-time Ca(2+) measurements were processed on field-stimulated intact cardiomyocytes with the selective 5-HT4R agonist, prucalopride (1 uM).
Name Type Language
PRUCALOPRIDE SUCCINATE
MART.   USAN   WHO-DD  
USAN  
Official Name English
PRUCALOPRIDE SUCCINATE [USAN]
Common Name English
PRUCALOPRIDE SUCCINATE [MART.]
Common Name English
MOTEGRITY
Brand Name English
Prucalopride succinate [WHO-DD]
Common Name English
PRUCALOPRIDE (AS SUCCINATE)
Common Name English
BUTANEDIOIC ACID, COMPD. WITH 4-AMINO-5-CHLORO-2,3-DIHYDRO-N-(1-(3-METHOXYPROPYL)-4-PIPERIDINYL)-7-BENZOFURANCARBOXAMIDE (1:1)
Common Name English
RESOLOR
Brand Name English
PRUCALOPRIDE SUCCINATE [ORANGE BOOK]
Common Name English
R-108512
Code English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
EMA ASSESSMENT REPORTS RESOLOR (AUTHORIZED: CONSTIPATION)
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
Code System Code Type Description
USAN
YY-101
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
EPA CompTox
DTXSID701027749
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
FDA UNII
4V2G75E1CK
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
PUBCHEM
9870009
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
EVMPD
SUB28850
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
RXCUI
2107309
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
NCI_THESAURUS
C152112
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
CAS
179474-85-2
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
SMS_ID
100000092989
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
ChEMBL
CHEMBL117287
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
DRUG BANK
DBSALT002626
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY
DAILYMED
4V2G75E1CK
Created by admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
PRIMARY